Idera squelches any lingering enthusiasm as its lead TLR9 drug flunks PhIII — badly
More than 3 years ago, with its stock riding high, Idera $IDRA caused quite a stir at ESMO with its TLR9 drug and the 44% ORR it tracked in a handful of patients suffering from advanced melanoma. The ORR for the Toll-like receptor 9 agonist dropped to 22% in Phase II. And on Thursday, the Phase III — its lead program — came out with a miserable 8.8% ORR for its combo approach using ipilimumab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.